Literature DB >> 12810549

Increased dietary fat attenuates the anorexic effects of intracerebroventricular injections of MTII.

Deborah J Clegg1, Stephen C Benoit, Ellen L Air, Alana Jackman, Patrick Tso, David D'Alessio, Stephen C Woods, Randy J Seeley.   

Abstract

The hypothalamic melanocortin (MC) system provides a critical inhibitory control on food intake and body weight. Because access to high-fat (HF) diets is associated with the development of obesity, we hypothesized that increased dietary fat attenuates signaling through the MC system. To evaluate this hypothesis, we compared the efficacy of the MC3/4 receptor agonist, MTII, to reduce food intake in rats fed carefully matched HF or low-fat (LF) diets for 12 wk. Rats given the HF diet ad libitum were significantly more obese than rats given the LF diet, and had significantly higher plasma insulin and leptin levels. MTII given into the third cerebral ventricle in doses of 0.1, 0.3, and 1.0 nmol was less effective at reducing food intake in HF rats than in LF rats. Whole-hypothalamic expression of the MC agonist precursor gene, proopiomelanocortin, the MC antagonist agouti-related protein, and the MC4 receptor, were not different between the HF and LF groups. These results indicate that consumption of a HF diet decreases signaling through the melanocortin system, an abnormality that could contribute to diet-induced obesity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810549     DOI: 10.1210/en.2002-0218

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  14 in total

1.  Energy balance and hypothalamic effects of a high-protein/low-carbohydrate diet.

Authors:  Kimberly P Kinzig; Sara L Hargrave; Jayson Hyun; Timothy H Moran
Journal:  Physiol Behav       Date:  2007-04-22

2.  High-fat intake induced by mu-opioid activation of the nucleus accumbens is inhibited by Y1R-blockade and MC3/4R- stimulation.

Authors:  Huiyuan Zheng; R Leigh Townsend; Andrew C Shin; Laurel M Patterson; Curtis B Phifer; Hans-Rudolf Berthoud
Journal:  Brain Res       Date:  2010-03-24       Impact factor: 3.252

3.  Mild lipid stress induces profound loss of MC4R protein abundance and function.

Authors:  Faith K Cragle; Giulia Baldini
Journal:  Mol Endocrinol       Date:  2014-02-07

Review 4.  The MC4 receptor and control of appetite.

Authors:  R A H Adan; B Tiesjema; J J G Hillebrand; S E la Fleur; M J H Kas; M de Krom
Journal:  Br J Pharmacol       Date:  2006-10-16       Impact factor: 8.739

5.  Differential body weight and feeding responses to high-fat diets in rats and mice lacking cholecystokinin 1 receptors.

Authors:  Sheng Bi; Jie Chen; R Ryan Behles; Jayson Hyun; Alan S Kopin; Timothy H Moran
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-04-04       Impact factor: 3.619

6.  mu-Opioid receptor stimulation in the nucleus accumbens elevates fatty tastant intake by increasing palatability and suppressing satiety signals.

Authors:  Yoshihiro Katsuura; Jennifer A Heckmann; Sharif A Taha
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-05-04       Impact factor: 3.619

7.  Access conditions affect binge-type shortening consumption in rats.

Authors:  F H E Wojnicki; D S Johnson; R L W Corwin
Journal:  Physiol Behav       Date:  2008-09-26

Review 8.  Implications of crosstalk between leptin and insulin signaling during the development of diet-induced obesity.

Authors:  Christopher D Morrison; Peter Huypens; Laura K Stewart; Thomas W Gettys
Journal:  Biochim Biophys Acta       Date:  2008-09-25

9.  Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion.

Authors:  John M Stafford; Fang Yu; Richard Printz; Alyssa H Hasty; Larry L Swift; Kevin D Niswender
Journal:  Diabetes       Date:  2008-03-10       Impact factor: 9.461

10.  Changes in feeding and locomotion induced by amphetamine analogs in rats.

Authors:  Paul J Wellman; Kristina W Davis; P Shane Clifford; Richard B Rothman; Bruce E Blough
Journal:  Drug Alcohol Depend       Date:  2008-12-04       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.